Healthcare >> CEO Interviews >> December 14, 1998

John C. Martin – Gilead Sciences Inc (gild)

DR. JOHN C. MARTIN has been President and CEO of Gilead Sciences, Inc. since April 1996. He joined the company in October 1990 as Vice President for Research and Development, was appointed Chief Operating Officer in November 1995 and was appointed President and Chief Executive Officer and elected to the Gilead Board of Directors in April 1996. From 1984 to 1990 he was employed at Bristol-Myers Squibb, where he was Director of Antiviral Chemistry. Prior to Bristol-Myers Squibb, Dr. Martin was employed at Syntex Corporation from 1978 to 1984. Dr. Martin is the co-inventor of ganciclovir, a pharmaceutical now marketed by Syntex for the treatment of cytomegalovirus infection. He is currently President of the International Society for Antiviral Research. Dr. Martin received his PhD in Organic Chemistry from the University of Chicago. Profile
TWST: Can we start out by your giving us a brief overview of Glead

Sciences, your history, your activities?

Mr. Martin: Gilead Sciences is a biotechnology company that's about 10

years old.